Clinical Trial Update: Efficacy and Safety of AK112 Combined Chemotherapy as Neoadjuvant Treatment for Signet Ring Cell-containing G/GEJ Adenocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating AK112 in combination with chemotherapy as neoadjuvant therapy for signet ring cell-containing gastric or gastroesophageal junction…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• AK112

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: NOT_YET_RECRUITING